Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.
Rusconi S, Vitiello P, Adorni F, Colella E, Focà E, Capetti A, Meraviglia P, Abeli C, Bonora S, D'Annunzio M, Di Biagio A, Di Pietro M, Butini L, Orofino G, Colafigli M, d'Ettorre G, Francisci D, Parruti G, Soria A, Buonomini AR, Tommasi C, Mosti S, Bai F, Di Nardo Stuppino S, Morosi M, Montano M, Tau P, Merlini E, Marchetti G. Rusconi S, et al. Among authors: meraviglia p. PLoS One. 2013 Nov 14;8(11):e80157. doi: 10.1371/journal.pone.0080157. eCollection 2013. PLoS One. 2013. PMID: 24244635 Free PMC article. Clinical Trial.
Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Bini T, Monforte Ad. Bongiovanni M, et al. Among authors: meraviglia p. Int J Antimicrob Agents. 2005 Jul;26(1):88-91. doi: 10.1016/j.ijantimicag.2005.03.003. Int J Antimicrob Agents. 2005. PMID: 15878262
Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis).
Rusconi S, Gianotti N, Adorni F, Boeri E, Menzo S, Gonnelli A, Micheli V, Meraviglia P, Trezzi M, Paolini E, Giacometti A, Corsi P, Di Pietro M, Monno L, Punzi G, Zazzi M; ARCA Collaborative Group. Rusconi S, et al. Among authors: meraviglia p. J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):373-5. doi: 10.1097/QAI.0b013e3181378f73. J Acquir Immune Defic Syndr. 2007. PMID: 18090302 No abstract available.
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.
Skowron G, Spritzler JG, Weidler J, Robbins GK, Johnson VA, Chan ES, Asmuth DM, Gandhi RT, Lie Y, Bates M, Pollard RB; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences. Skowron G, et al. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):250-8. doi: 10.1097/QAI.0b013e3181938faf. J Acquir Immune Defic Syndr. 2009. PMID: 19194319 Free PMC article. Clinical Trial.
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.
Bracciale L, Colafigli M, Zazzi M, Corsi P, Meraviglia P, Micheli V, Maserati R, Gianotti N, Penco G, Setti M, Di Giambenedetto S, Butini L, Vivarelli A, Trezzi M, De Luca A. Bracciale L, et al. Among authors: meraviglia p. J Antimicrob Chemother. 2009 Sep;64(3):607-15. doi: 10.1093/jac/dkp246. Epub 2009 Jul 16. J Antimicrob Chemother. 2009. PMID: 19608581
No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy.
Gianotti N, Galli L, Zazzi M, Ghisetti V, Bonora S, Micheli V, Meraviglia P, Corsi P, Bruzzone B, Menzo S, Di Giambenedetto S, De Luca A, Filice G, Penco G, Castagna A; ARCA database initiative. Gianotti N, et al. Among authors: meraviglia p. J Med Virol. 2011 Mar;83(3):391-8. doi: 10.1002/jmv.21989. J Med Virol. 2011. PMID: 21264858
97 results